- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
- Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
More ▼
Key statistics
On Friday, Sagimet Biosciences Inc (SGMT:NMQ) closed at 5.33, 150.23% above the 52 week low of 2.13 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.50 |
---|---|
High | 5.60 |
Low | 5.15 |
Bid | 5.22 |
Offer | 5.44 |
Previous close | 5.40 |
Average volume | 614.27k |
---|---|
Shares outstanding | 31.91m |
Free float | 26.05m |
P/E (TTM) | -- |
Market cap | 170.10m USD |
EPS (TTM) | -1.23 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼